Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 1

Conditions

Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × Rosiglitazone × Clear all
NCT00616642 2020-08-14

Rosiglitazone in Treating Patients With Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
1 enrolled 4 charts
CNSEndocrine

Pituitary Neoplasms, Central Nervous System Neoplasms

NCT00612066 2020-08-06

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 5 charts
Endocrine

Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡